Hormone Combo Therapy Shows Promise for Menopausal Mood and Sexual Health
Study compares estrogen-androgen combination vs estrogen alone for psychological symptoms and sexuality in postmenopausal women.
Summary
This clinical trial investigated whether combining estrogen with a weak androgen (DHEA) provides superior relief for psychological complaints and sexual dysfunction compared to estrogen-only therapy in postmenopausal women. The study enrolled 140 participants in a crossover design where women received both treatments in different sequences over 10 cycles. All participants with intact uteruses also received progesterone to prevent endometrial overgrowth. The research aimed to address the broader spectrum of menopausal symptoms beyond hot flashes, focusing specifically on mood, anxiety, depression, and sexual interest that significantly impact quality of life during menopause.
Detailed Summary
This Bayer-sponsored clinical trial examined whether Gynodian Depot, a combination of estrogen and the weak androgen DHEA, provides superior relief for psychological and sexual symptoms compared to estrogen-only therapy in postmenopausal women. The study addressed a critical gap in menopause treatment by focusing on mood, anxiety, depression, and sexual dysfunction rather than just vasomotor symptoms.
The trial used a crossover design with 140 participants randomly assigned to receive either Gynodian Depot followed by estradiol valerate, or the reverse sequence. Each treatment phase lasted five cycles with monthly intramuscular injections. Women with intact uteruses received additional progesterone supplementation to prevent endometrial complications.
Participants underwent comprehensive evaluations including psychological questionnaires, hormone level assessments, gynecological examinations, and safety monitoring over 11 months with 16 scheduled visits. The study measured changes in menopausal symptoms, sexual function, and overall well-being while monitoring for adverse effects.
While the trial has completed, specific results regarding the comparative effectiveness of combination hormone therapy versus estrogen alone remain to be fully published. This research is particularly relevant for longevity-focused individuals as hormonal optimization during menopause may influence long-term health outcomes including bone density, cardiovascular health, and cognitive function. The study's focus on psychological well-being and sexual health addresses quality-of-life factors that significantly impact healthy aging and relationship satisfaction in postmenopausal women.
Key Findings
- Crossover trial design allowed each participant to serve as their own control
- Study focused on psychological symptoms and sexual dysfunction, not just hot flashes
- Combined estrogen-androgen therapy compared against estrogen-only treatment
- 140 postmenopausal women completed comprehensive 11-month evaluation protocol
Methodology
Randomized crossover trial with 140 participants over 11 months. Each woman received both treatments in different sequences, serving as her own control across 10 treatment cycles with monthly injections.
Study Limitations
Specific efficacy results not detailed in available summary. Single-sponsor study may introduce bias. Crossover design requires washout period consideration between treatments.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.